Sernova Corp. (SEOVF)
USD 0.13
(0.15%)
USD 0.13
(0.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 136.12 Thousand CAD | -50.68% |
| 2022 | 275.97 Thousand CAD | -29.84% |
| 2021 | 393.35 Thousand CAD | -44.02% |
| 2020 | 702.61 Thousand CAD | 0.0% |
| 2019 | - CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | -100.0% |
| 2005 | 87.65 Thousand CAD | -5.4% |
| 2004 | 92.65 Thousand CAD | 0.0% |
| 2003 | - CAD | 0.0% |
| 2002 | - CAD | 0.0% |
| 2001 | - CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 592.23 Thousand CAD | -3.51% |
| 2024 Q1 | 634.63 Thousand CAD | 366.22% |
| 2024 Q2 | 613.78 Thousand CAD | -3.28% |
| 2023 Q4 | 136.12 Thousand CAD | -21.54% |
| 2023 Q1 | 243.08 Thousand CAD | -11.92% |
| 2023 Q3 | 173.48 Thousand CAD | -16.96% |
| 2023 Q2 | 208.93 Thousand CAD | -14.05% |
| 2023 FY | 136.12 Thousand CAD | -50.68% |
| 2022 Q4 | 275.97 Thousand CAD | -10.22% |
| 2022 Q1 | 365.76 Thousand CAD | -7.01% |
| 2022 FY | 275.97 Thousand CAD | -29.84% |
| 2022 Q2 | 337.12 Thousand CAD | -7.83% |
| 2022 Q3 | 307.39 Thousand CAD | -8.82% |
| 2021 Q4 | 393.35 Thousand CAD | 0.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2021 FY | 393.35 Thousand CAD | -44.02% |
| 2021 Q1 | - CAD | -100.0% |
| 2021 Q3 | - CAD | 0.0% |
| 2020 Q2 | 37.87 Thousand CAD | -41.79% |
| 2020 FY | 702.61 Thousand CAD | 0.0% |
| 2020 Q1 | 65.06 Thousand CAD | 0.0% |
| 2020 Q3 | 9645.00 CAD | -74.53% |
| 2020 Q4 | 702.61 Thousand CAD | 7184.73% |
| 2019 FY | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 FY | - CAD | -100.0% |
| 2006 Q1 | 87.65 Thousand CAD | 0.0% |
| 2006 Q2 | - CAD | -100.0% |
| 2005 Q1 | - CAD | -100.0% |
| 2005 Q2 | 87.65 Thousand CAD | 0.0% |
| 2005 FY | 87.65 Thousand CAD | -5.4% |
| 2005 Q3 | 87.65 Thousand CAD | 0.0% |
| 2005 Q4 | 87.65 Thousand CAD | 0.0% |
| 2004 Q4 | 92.65 Thousand CAD | 12.78% |
| 2004 Q2 | 315.25 Thousand CAD | 0.0% |
| 2004 FY | 92.65 Thousand CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q3 | 82.15 Thousand CAD | -73.94% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q1 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2002 Q2 | - CAD | 0.0% |
| 2002 Q3 | - CAD | 0.0% |
| 2002 Q4 | - CAD | 0.0% |
| 2002 Q1 | - CAD | 0.0% |
| 2002 FY | - CAD | 0.0% |
| 2001 FY | - CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.33% |
| Skye Bioscience, Inc. | 4.61 Million USD | 97.051% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.543% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -11.121% |
| Qrons Inc. | 351.84 Thousand USD | 61.312% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 97.111% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.686% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.681% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 81.999% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.701% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | 56.089% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 78.396% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -429.27% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.67% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 96.698% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 66.126% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.504% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 94.148% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 85.645% |
| Mesoblast Limited | 118.7 Million USD | 99.885% |
| Marizyme, Inc. | 18.71 Million USD | 99.273% |
| Genus plc | 233.1 Million USD | 99.942% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 95.355% |
| Pharming Group N.V. | 171.54 Million USD | 99.921% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 84.672% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 89.869% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 81.85% |
| ContraFect Corporation | 2.88 Million USD | 95.275% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -0.469% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 90.588% |
| IMV Inc. | 28.88 Million USD | 99.529% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 97.594% |
| MultiCell Technologies, Inc. | 202.58 USD | -67094.689% |
| ONE Bio Corp. | 19.71 Million USD | 99.31% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.763% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 90.893% |
| Q BioMed Inc. | 4.1 Million USD | 96.688% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.589% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 88.918% |
| Biomind Labs Inc. | 735.54 Thousand USD | 81.494% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.799% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 95.502% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.953% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 62.158% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 3.812% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 93.973% |
| GB Sciences, Inc. | 1.75 Million USD | 92.263% |
| Alpha Cognition Inc. | 1.22 Million USD | 88.846% |
| HST Global, Inc. | 98.31 Thousand USD | -38.45% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 45.271% |
| Halberd Corporation | 150 Thousand USD | 9.251% |
| Enzolytics Inc. | 996.33 Thousand USD | 86.338% |
| Agentix Corp. | 50 Thousand USD | -172.246% |
| Resverlogix Corp. | 6.49 Million USD | 97.903% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 46.742% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 99.319% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.075% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.975% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1231.276% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.967% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 32.147% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 94.323% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 40.633% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 8.43% |
| Kadimastem Ltd | 891.22 Thousand USD | 84.726% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 45.59% |
| LadRx Corporation | 33.6 Thousand USD | -305.056% |
| Cell Source, Inc. | 9.25 Million USD | 98.529% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 81.999% |
| NovAccess Global Inc. | 2.19 Million USD | 93.812% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | 40.395% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 35.479% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 97.268% |
| Mobile Lads Corp. | 484.28 Thousand USD | 71.892% |
| CytoDyn Inc. | 30.07 Million USD | 99.547% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.259% |
| SYBLEU INC | 477.5 Thousand USD | 71.493% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 97.125% |
| International Stem Cell Corporation | 4.17 Million USD | 96.742% |
| Bioxytran, Inc. | 1.92 Million USD | 92.929% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -118.1% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.758% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.363% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.414% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 91.249% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 49.208% |
| Neutra Corp. | 54.15 Thousand USD | -151.353% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 92.562% |
| PureTech Health plc | 25.51 Million USD | 99.466% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 88.881% |
| IXICO plc | 472.02 Thousand USD | 71.162% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.122% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.781% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.853% |